Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer - Summary - MDSpire

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • By

  • Yulu Wang

  • Chengyang Luo

  • Yueze Li

  • Jiayu Pei

  • Dian Wang

  • Pei Wang

  • Jing Li

  • June 12, 2026

  • 0 min

Share

Objective:

To develop an inflammatory biomarker-based prediction model to identify patients with advanced cervical cancer who may benefit from anti-PD-1/PD-L1 therapy.

Key Findings:
  • The LASSO-Cox model demonstrated strong predictive performance.
  • Calibration curves confirmed consistency between predicted and observed overall survival (OS) or progression-free survival (PFS).
Interpretation:

Limitations:
  • Consider adding any limitations mentioned in the source.
Conclusion:

Revise to remove unsupported claims about clinical guidance.

Original Source(s)

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • by Yulu Wang, Chengyang Luo, Yueze Li, Jiayu Pei, Dian Wang, Pei Wang, Jing Li

  • June 12, 2026

Related Content

The future of neurosurgical oncology lies in cognitive neurosciences: understanding brain processing is much more valuable than surgical technology

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

A federated digital twin reveals cytomegalovirus reactivation impairs CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma